| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website https://jmc.elmerpub.com |
Case Report
Volume 17, Number 9, September 2026, pages 503-508
Reproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson’s Disease
Table
| Medication regimens |
|---|
| Producing heat symptoms (per history) |
| (1) Levodopa–benserazide monotherapy (unspecified formulation and dose) |
| (2) Levodopa–carbidopa monotherapy (100/25 mg TID) |
| (3) Combined levodopa–carbidopa (100/25 mg TID) and ropinirole (2 mg OD) |
| (4) Combined levodopa–carbidopa (125/12.5 mg QID), rasagiline (0.5 mg OD), and rotigotine patch (2 mg OD) |
| Producing heat symptoms (rechallenged) |
| (1) Levodopa–carbidopa (50/12.5–100/25 mg; dose-dependent intensity) |
| (2) Levodopa–benserazide (regular tablet; 50/12.5 mg) |
| (3) Levodopa–benserazide (orodispersible tablet; 25/6.25 mg) |
| Not producing heat symptoms during medication trial |
| (1) Pramipexole monotherapy (0.25–0.625 mg QID) |
| (2) Combined pramipexole (0.25–0.625 mg QID) and selegiline (5–10 mg OD) |
| (3) Combined pramipexole (0.25–0.625 mg QID), selegiline (5–10 mg OD), and bromocriptine (1.25–2.5 mg BID) |
| (4) Rotigotine patch monotherapy (2–6 mg/day, OD) |